More tools:Markets·Screener·Research Chat

ResMed Inc. (RMD) Financial Statements

ResMed Inc.
SIC 3841 · SURGICAL & MEDICAL INSTRUMENTS & APPARATUS
FIGI BBG001SBGRC2
XNYS · usd
193.01▼ 5.49 (-2.77%)
As of 2026-07-14
Valuation
Market Cap
Enterprise Value
Trailing P/E
Price / Sales
EV / Revenue
EV / EBITDA
Financial Highlights
Revenue (TTM)$5.5B
Net Income (TTM)$1.5B
EBITDA
Diluted EPS (TTM)
EBITDA Margin38.2%
Net Debt
Trading Information
Previous Close198.50
Day's Range190.76 – 195.05
52-Week Range180.27 – 293.81
Volume1.62M
Avg Volume1.61M
Share Statistics
Shares Outstanding145.1M
Employees10.6K
ExchangeXNYS
Listed1995-06-02

Key questions about ResMed Inc. (RMD)

What is ResMed Inc.'s Market Cap?
ResMed Inc.'s Market Cap is $28.0B, based on as-reported figures from SEC (XBRL) filings.
What is ResMed Inc.'s Enterprise Value?
ResMed Inc.'s Enterprise Value is $28.8B, based on as-reported figures from SEC (XBRL) filings.
What is ResMed Inc.'s Trailing P/E?
ResMed Inc.'s Trailing P/E is 18.4×, based on as-reported figures from SEC (XBRL) filings.
What is ResMed Inc.'s Price / Sales?
ResMed Inc.'s Price / Sales is 5.1×, based on as-reported figures from SEC (XBRL) filings.
What is ResMed Inc.'s EV / Revenue?
ResMed Inc.'s EV / Revenue is 5.2×, based on as-reported figures from SEC (XBRL) filings.
What is ResMed Inc.'s EV / EBITDA?
ResMed Inc.'s EV / EBITDA is 13.6×, based on as-reported figures from SEC (XBRL) filings.
What is ResMed Inc.'s Revenue (TTM)?
ResMed Inc.'s Revenue (TTM) is $5.5B, based on as-reported figures from SEC (XBRL) filings.
What is ResMed Inc.'s Net Income (TTM)?
ResMed Inc.'s Net Income (TTM) is $1.5B, based on as-reported figures from SEC (XBRL) filings.
What is ResMed Inc.'s EBITDA?
ResMed Inc.'s EBITDA is $2.1B, based on as-reported figures from SEC (XBRL) filings.
What is ResMed Inc.'s Diluted EPS (TTM)?
ResMed Inc.'s Diluted EPS (TTM) is 10.48, based on as-reported figures from SEC (XBRL) filings.
Loading Income Statement…
Showing the most recent year. Subscribe for full statement history.
Income Statement(in millions of USD, except per-share data)
Source: Akyla.ai
Line ItemMar 31, 2026Dec 31, 2025Sep 30, 2025Jun 30, 2025Mar 31, 2025Dec 31, 2024Sep 30, 2024Jun 30, 2024Mar 31, 2024Dec 31, 2023Sep 30, 2023Jun 30, 2023Mar 31, 2023Dec 31, 2022Sep 30, 2022Jun 30, 2022
Net revenue - Sleep and Breathing Health products
Net revenue - Residential Care Software
Net revenue
YoY growth+10.8%+11.0%+9.1%+10.2%
Cost of sales - Sleep and Breathing Health products
Cost of sales - Residential Care Software
Cost of sales (exclusive of amortization shown separately below)
Amortization of acquired intangible assets - Sleep and Breathing Health products
Amortization of acquired intangible assets - Residential Care Software
Amortization of acquired intangible assets
Total cost of sales
Gross profit
% of revenue62.2%61.8%61.5%60.8%
Selling, general, and administrative
Research and development
Total operating expenses
% of revenue27.3%27.2%28.0%27.1%
Income from operations
% of revenue34.9%34.6%33.4%33.7%
Other income (loss), net:
Interest (expense) income, net
Other, net
Total other income (loss), net
Income before income taxes
Income taxes
Net income
% of revenue27.9%27.6%26.1%28.2%
Dividend declared per share————